Today: 10 March 2026
Subscribe
Browse Category

NYSE:PFE 28 January 2026 - 9 March 2026

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.
6 February 2026
···
Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer shares fell 1.1% to $26.49 in premarket trading after the TrumpRx discount drug portal launched Thursday, raising concerns over U.S. drug pricing. Pfizer said its TrumpRx program offers discounts of up to 85% on more than 30 medicines. The FDA granted Priority Review for expanding Hympavzi use in younger hemophilia patients, with a decision expected in the second quarter.
6 February 2026
··
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 February 2026
·
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
··
Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 February 2026
··
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer shares fell 3.4% to $25.76 early Tuesday after quarterly results and new Phase 2b obesity drug data. The company reported adjusted Q4 earnings of 66 cents per share on $17.56 billion revenue, both above analyst estimates. Pfizer reaffirmed its 2026 outlook and does not plan share buybacks this year. COVID-19 product sales continued to decline sharply.
3 February 2026
··
Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer shares rose 0.3% to $26.51 ahead of fourth-quarter and full-year 2025 results due Feb. 3. Analysts expect adjusted earnings of 57–58 cents per share on $16.7–16.9 billion revenue. Obesity drug price cuts and a UK ruling against Sanofi in an RSV dispute add pressure. Pfizer projects 2026 revenue of $59.5–62.5 billion, factoring in losses from COVID-19 products and patent expirations.
2 February 2026
·
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
1 2 3 … 9
Go toTop